<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="197792">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515944</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 60201-0709/1</org_study_id>
    <nct_id>NCT00515944</nct_id>
  </id_info>
  <brief_title>Evaluate the Migration Potential of Xeomin速 Compared to Two Other Botulinum Toxin Type A Products</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <brief_summary>
    <textblock>
      Xeomin速 is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free
      of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin速 causes
      local weakening. Botulinum toxin type A is used for certain neurological and aesthetic
      treatments. This study will investigate the migration potential of Xeomin速.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conducted in Europe
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of area</measure>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum neurotoxin type A, free of complexing proteins</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy females, 18 to 65 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merz Pharmaceuticals GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>61273</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <lastchanged_date>March 31, 2009</lastchanged_date>
  <firstreceived_date>August 13, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Clinical Pharmacology</name_title>
    <organization>Merz Pharmaceuticals</organization>
  </responsible_party>
  <keyword>No condition</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
